Juan Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Du has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Qiang Yu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
4 shared publications - Chun-Hao Zhu
College of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China
2 shared publications - Jia-Mei Yang
Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China
2 shared publications Lin Ma
Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China
2 shared publications- Lin Ma
Department of Pharmacology, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, China
2 shared publications - Miao-Miao Tian
Key Laboratory of Protection, Development, and Utilization of Medicinal Resources in Liupanshan Area, Ministry of Education, Department of Pharmacology, Peptide & Protein Drug Research Center, College of Pharmacy, School of Pharmacy, Ningxia Medical University, Yinchuan, China
2 shared publications
Latest Publications
- Open Access
ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity
- 26 August 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 957, 176003
Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges
- 26 August 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 957, 176003
Neuroprotective strategies for neonatal hypoxic-ischemic brain damage: Current status and challenges
- 11 March 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 947, 175646
Targeting the chemokine ligand 2–chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain
- 11 March 2023
- Published by Elsevier in European Journal of Pharmacology
- Vol. 947, 175646
Targeting the chemokine ligand 2–chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain
- Open Access
- 27 September 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 155, 113731
Development of protective agents against ovarian injury caused by chemotherapeutic drugs
- 27 September 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 155, 113731
Open AccessDevelopment of protective agents against ovarian injury caused by chemotherapeutic drugs
- Open Access
Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components
Neuropathic pain is a refractory disease that occurs across the world and pharmacotherapy has limited efficacy and/or safety. This disease imposes a significant burden on both the somatic and mental health of patients; indeed, some patients have referred to neuropathic pain as being ‘worse than death’. The pharmacological agents that are used to treat neuropathic pain at present can produce mild effects in certain patients, and induce many adverse reactions, such as sedation, dizziness, vomiting, and peripheral oedema. Therefore, there is an urgent need to discover novel drugs that are safer and more effective. Natural compounds from medical plants have become potential sources of analgesics, and evidence has shown that glycosides alleviated neuropathic pain via regulating oxidative stress, transcriptional regulation, ion channels, membrane receptors and so on. In this review, we summarize the epidemiology of neuropathic pain and the existing therapeutic drugs used for disease prevention and treatment. We also demonstrate how glycosides exhibit an antinociceptive effect on neuropathic pain in laboratory research and describe the antinociceptive mechanisms involved to facilitate the discovery of new drugs to improve the quality of life of patients experiencing neuropathic pain.
Open AccessGlycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components
Neuropathic pain is a refractory disease that occurs across the world and pharmacotherapy has limited efficacy and/or safety. This disease imposes a significant burden on both the somatic and mental health of patients; indeed, some patients have referred to neuropathic pain as being ‘worse than death’. The pharmacological agents that are used to treat neuropathic pain at present can produce mild effects in certain patients, and induce many adverse reactions, such as sedation, dizziness, vomiting, and peripheral oedema. Therefore, there is an urgent need to discover novel drugs that are safer and more effective. Natural compounds from medical plants have become potential sources of analgesics, and evidence has shown that glycosides alleviated neuropathic pain via regulating oxidative stress, transcriptional regulation, ion channels, membrane receptors and so on. In this review, we summarize the epidemiology of neuropathic pain and the existing therapeutic drugs used for disease prevention and treatment. We also demonstrate how glycosides exhibit an antinociceptive effect on neuropathic pain in laboratory research and describe the antinociceptive mechanisms involved to facilitate the discovery of new drugs to improve the quality of life of patients experiencing neuropathic pain.